Edwards, J.C., Leandro, M.J., and Cambridge, G.: B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr. Dir. Autoimmun. 2005, 8:175–192.
Yazawa, N., Hamaguchi, Y., Poe, J.C., and Tedder, T.F.: Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl Acad. Sci. USA 2005, 102:15178–15783.
Zaja, F., De Vita, S., Mazzaro, C., Sacco, S., Damiani, D., De Marchi, G., Michelutti, A., Baccarani, M., Fanin, R., and Ferraccioli, G.: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101:3827–3834.
16-8 Biologic agents that block TNF-α, IL-1, or IL-6 can alleviate autoimmune diseases.
Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., Farlik, M., Decker, T., Du Pasquier, R.A., Romero, P., et al.: Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011, 34:213–223.
Feldmann, M., and Maini, R.N.: Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 2003, 9:1245–1250.
Hallegua, D.S., and Weisman, M.H.: Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann. Rheum. Dis. 2002, 61:960–967.
Karanikolas, G., Charalambopoulos, D., Vaiopoulos, G., Andrianakos, A., Rapti, A., Karras, D., Kaskani, E., and Sfikakis, P.P.: Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. Rheumatology 2008, 47:1384–1388.
Mackay, C.R.: New avenues for anti-inflammatory therapy. Nat. Med. 2002, 8:117–118.
16-9 Biologic agents can block cell migration to sites of inflammation and reduce immune responses.
Boster, A.L., Nicholas, J.A., Topalli, I., Kisanuki, Y.Y., Pei, W., Morgan-Followell, B., Kirsch, C.F., Racke, M.K., and Pitt, D.: Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol. 2013, 70:398–402.
Clifford, D.B., De Luca, A., Simpson, D.M., Arendt, G., Giovannoni, G., and Nath, A.: Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010, 9:438–446.